secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0001193125-23-164444
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea shareholders approve reverse stock split; equity incentive plan fails
----------------------------------------------------------------------------

- Alison Lawton and Hunter C. Smith elected as Class I directors with 26.8M and 33.8M shares for, respectively.
- Ratification of PwC as auditor for FY 2023 approved with 46.9M shares for, 4.1M against.
- Reverse stock split (1:10 to 1:25 ratio) approved by 44.1M shares for vs 5.5M against; board to select ratio.
- Amendment and restatement of 2016 Equity Incentive Plan defeated: 19.1M for vs 19.3M against (excluding broker non-votes).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523164444/0001193125-23-164444-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523164444/d492050d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-164444

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer